Aurinia Pharmaceuticals Inc Ordinary Shares
AUPH CA05156V1022
💰
Capitalization
Small-cap
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
🔗
Website
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 69% | -81% | 51% | 3% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
📊
Transactions
39
🙍
Insiders
15
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Tang Kevin O |
11.68 USD |
200,000 Bought |
2,336,000 USD |
01/08/2025 | 05/08/2025 |
| Tang Kevin O |
11.34 USD |
100,000 Bought |
1,134,000 USD |
01/08/2025 | 04/08/2025 |
| Tang Kevin O |
10.12 USD |
1,000,000 Bought |
10,120,000 USD |
01/08/2025 | 01/08/2025 |
| Keenan Greg CMO |
10.50 USD |
20,000 Sold |
210,000 USD |
01/08/2025 | 01/08/2025 |
| Keenan Greg CMO |
8.23 USD |
8,305 Sold |
68,350 USD |
07/03/2025 | 07/03/2025 |
| Tang Kevin O |
8.00 USD |
148,038 Bought |
1,184,304 USD |
28/02/2025 | 04/03/2025 |
| Miller Joseph M CFO |
7.92 USD |
56,154 Sold |
444,740 USD |
28/02/2025 | 04/03/2025 |
| Tang Kevin O |
8.09 USD |
100,000 Bought |
809,000 USD |
28/02/2025 | 04/03/2025 |
| Greenleaf Peter CEO |
7.92 USD |
164,947 Sold |
1,306,380 USD |
28/02/2025 | 04/03/2025 |
| Donley Matthew Maxwell COO |
7.92 USD |
58,991 Sold |
467,209 USD |
28/02/2025 | 04/03/2025 |